Urothelial Bladder Cancer — Microlearning Activity 2 with Dr Terence Friedlander: ESMO Congress 2025 Review
Oncology Today with Dr Neil Love
00:00
T-DXd (destiny) in bladder cancer
Terence summarizes DESTINY pan-tumor bladder data: high responses in HER2 3+, FDA approval, and PFS nuances.
Play episode from 12:25
Transcript
